# Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer

> **NCT06973421** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 35 (estimated)

## Conditions studied

- Platinum Resistant Ovarian Cancer

## Interventions

- **DRUG:** Utidelone Capsules
- **DRUG:** Fruquintinib Capsules

## Key facts

- **NCT ID:** NCT06973421
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06973421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06973421, "Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06973421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*